- Home
- CISO vs KALA Comparison
CISO vs KALA Comparison
Compare CISO & KALA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CISO
- KALA
- Stock Information
- Founded
- CISO 2015
- KALA 2009
- Country
- CISO United States
- KALA United States
- Employees
- CISO N/A
- KALA N/A
- Industry
- CISO Computer Software: Prepackaged Software
- KALA Biotechnology: Pharmaceutical Preparations
- Sector
- CISO Technology
- KALA Health Care
- Exchange
- CISO Nasdaq
- KALA Nasdaq
- Market Cap
- CISO 31.4M
- KALA 26.2M
- IPO Year
- CISO N/A
- KALA 2017
- Fundamental
- Price
- CISO $1.01
- KALA $7.14
- Analyst Decision
- CISO
- KALA Strong Buy
- Analyst Count
- CISO 0
- KALA 3
- Target Price
- CISO N/A
- KALA $14.00
- AVG Volume (30 Days)
- CISO 794.2K
- KALA 198.2K
- Earning Date
- CISO 08-13-2025
- KALA 08-05-2025
- Dividend Yield
- CISO N/A
- KALA N/A
- EPS Growth
- CISO N/A
- KALA N/A
- EPS
- CISO N/A
- KALA N/A
- Revenue
- CISO $29,887,603.00
- KALA N/A
- Revenue This Year
- CISO N/A
- KALA N/A
- Revenue Next Year
- CISO N/A
- KALA N/A
- P/E Ratio
- CISO N/A
- KALA N/A
- Revenue Growth
- CISO N/A
- KALA N/A
- 52 Week Low
- CISO $0.26
- KALA $2.92
- 52 Week High
- CISO $3.84
- KALA $11.20
- Technical
- Relative Strength Index (RSI)
- CISO 43.38
- KALA 59.52
- Support Level
- CISO $1.03
- KALA $5.35
- Resistance Level
- CISO $1.15
- KALA $8.49
- Average True Range (ATR)
- CISO 0.08
- KALA 0.81
- MACD
- CISO -0.01
- KALA 0.17
- Stochastic Oscillator
- CISO 16.67
- KALA 57.01
About CISO CISO Global Inc.
CISO Global Inc provides cybersecurity services. The services are used to protect client's data, financial information, intellectual property, and business reputation. The services include penetration testing, security remediation, compliance auditing, vulnerability assessment, and others. Geographically, the company operates in U.S., Chile and All other countries. The maximum revenue is generated from U.S.
About KALA KALA BIO Inc.
Kala Bio Inc is a biopharmaceutical company. The company is a clinical-stage biopharmaceutical company dedicated to researching, developing, and commercializing therapies for rare and severe eye diseases. KALA'smain product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived biofactors, such as growth factors, protease inhibitors, matrix proteins, and neurotrophic factors that can potentially correct the impaired corneal healing that is an underlying etiology of multiple severe ocular diseases. Its MSC-S platform is for retinal degenerative diseases, such as Retinitis Pigmentosa and Stargardt Disease.